{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=8", "query": { "intervention": "cohort 3", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 5403, "total_pages": 541, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+3&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T12:54:45.097Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01911039", "title": "Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Graft Versus Host Disease", "Allogeneic Hematopoietic Cell Transplant Recipient" ], "interventions": [ { "name": "Regulatory T Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Laura Johnston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2013-07", "completion_date": "2018-07-31", "has_results": false, "last_update_posted_date": "2021-09-27", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01911039" }, { "nct_id": "NCT04092673", "title": "Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "eFT226", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-10-25", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 14, "location_summary": "Los Angeles, California • Newport Beach, California • Palo Alto, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04092673" }, { "nct_id": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Itraconazole (ITZ)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2023-11-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 20, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084481" }, { "nct_id": "NCT04494256", "title": "A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyotrophic Lateral Sclerosis" ], "interventions": [ { "name": "BIIB105", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2020-09-28", "completion_date": "2024-08-13", "has_results": true, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 14, "location_summary": "Phoenix, Arizona • La Jolla, California • Palo Alto, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04494256" }, { "nct_id": "NCT01770353", "title": "MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "ER/PR Positive Breast Cancer", "Triple Negative Breast Cancer", "Metastatic Breast Cancer With Active Brain Metastasis" ], "interventions": [ { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "MM-398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2012-11", "completion_date": "2018-10-02", "has_results": true, "last_update_posted_date": "2019-11-27", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01770353" }, { "nct_id": "NCT07559422", "title": "Ventriloscope Simulation Stethoscope Training in PT and AT Students (VENTAS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Auscultation Training", "Health Professions Education" ], "interventions": [ { "name": "Traditional Auscultation Training", "type": "BEHAVIORAL" }, { "name": "Ventriloscope Simulation Training", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Youngstown State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-05-11", "completion_date": "2026-10-19", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 1, "location_summary": "Youngstown, Ohio", "locations": [ { "city": "Youngstown", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07559422" }, { "nct_id": "NCT00002537", "title": "Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "1993-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002537" }, { "nct_id": "NCT05517902", "title": "StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Skin Wound", "Burns", "Trauma-related Wound" ], "interventions": [ { "name": "StrataGraft", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stratatech, a Mallinckrodt Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 1, "start_date": "2023-04-28", "completion_date": "2024-05-09", "has_results": true, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05517902" }, { "nct_id": "NCT03412565", "title": "A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2018-04-26", "completion_date": "2024-04-18", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 16, "location_summary": "Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more", "locations": [ { "city": "Southington", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412565" }, { "nct_id": "NCT03181867", "title": "18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Neoplasms", "Prostatic Cancer", "Prostate Cancer", "Cancer Of Prostate", "Metastatic Prostate Cancer" ], "interventions": [ { "name": "18F-DCFPyL", "type": "DRUG" }, { "name": "18F-FDG", "type": "DRUG" }, { "name": "PSMA-11", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 360, "start_date": "2017-08-03", "completion_date": "2031-02-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-09T12:54:45.097Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03181867" } ] }